Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity
LM-305 is a monoclonal antibody ADC product targeting the GPRC5D receptor, developed by Lixian Pharmaceuticals
Over the last decade, GLP-1 therapies have transformed diabetes and obesity treatment
This concept is powerful in an in-vitro context, allowing researchers to study the fundamental mechanisms of cellular aging and rejuvenation without the confounding variables of a whole organism
D'Alessio declares an association with the following companies: Amylin (research support, consulting), Johnson and Johnson (research support, scientific advisory boards, consulting), MannKind (research support), Merck (consulting), Novo Nordisk (scientific advisory board), Sanofi-Aventis (research support), Takeda (consulting)